Literature DB >> 15950329

The effectiveness of the mumps component of the MMR vaccine: a case control study.

Richard Harling1, Joanne M White, Mary E Ramsay, Karen F Macsween, Corry van den Bosch.   

Abstract

In 1998/1999, an outbreak of mumps occurred among children of a religious community in North East London. A case control study was conducted to assess the effectiveness of the mumps component of the MMR vaccine. One hundred and sixty-one cases of mumps were identified and 192 controls were selected. Fifty-one percent of cases and 77% of controls had a history at least one MMR vaccination. The observed effectiveness of any MMR vaccination adjusted for age, sex and general practice was 69% (95% CI: 41-84%). This is consistent with the results of other observational studies of mumps containing vaccines, but lower than the immunogenicity of mumps vaccines reported by clinical trials. This discrepancy is because observational studies tend to underestimate vaccine effectiveness, and because immunogenicity is not necessarily an accurate biological marker of vaccine effectiveness. Two doses of vaccine were more effective (88% (95% CI: 62-96%)) than a single dose (64% (95% CI: 40-78%)). The current two-dose vaccination programme remains the best method for controlling mumps infection in the community.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950329     DOI: 10.1016/j.vaccine.2004.10.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults.

Authors:  Gaynor Watson-Creed; Andrea Saunders; Jeffrey Scott; Luis Lowe; Janice Pettipas; Todd F Hatchette
Journal:  CMAJ       Date:  2006-08-29       Impact factor: 8.262

3.  Mumps outbreaks across England and Wales in 2004: observational study.

Authors:  Emma Savage; Mary Ramsay; Joanne White; Stuart Beard; Heather Lawson; Rashpal Hunjan; David Brown
Journal:  BMJ       Date:  2005-05-14

4.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

5.  Is mumps making a comeback?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-01       Impact factor: 2.471

6.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Authors:  Sabine Wicker; Holger F Rabenau; René Gottschalk; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-02       Impact factor: 3.402

7.  Update on available vaccines in India: report of the APPA VU 2010: I.

Authors:  Sunil Karande
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

8.  Outbreak of mumps in a school setting, United Kingdom, 2013.

Authors:  Erlend T Aasheim; Thomas Inns; Amy Trindall; Lynsey Emmett; Kevin E Brown; Chris J Williams; Mark Reacher
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps.

Authors:  Chuanxi Fu; Jianhua Liang; Ming Wang
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.